There were 1,517 press releases posted in the last 24 hours and 453,873 in the last 365 days.

MYnd Analytics’ Breakthrough Technology Featured on CBS New York

/EIN News/ -- NEW YORK, Nov. 16, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (OTCQB:MYAN), a predictive medicine company that provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry that reduces trial and error treatment in mental health, announced today it was featured on CBS New York by medical correspondent Dr. Max Gomez on Monday evening, November 14, 2016.

PEER technology uses algorithms and a database consisting of outcomes from more than 10,000 patients to generate an objective report which can help a physician select the appropriate mental health medication for an individual as opposed to “treatment as usual” which involves a significant degree of trial and error. This technology helped Col. Kelly Thrasher’s doctor find the right medication for him get his life back. “Getting on the right medication definitely saved my marriage, probably saved my life to tell you the truth,” Thrasher told Dr. Gomez.

Watch the CBS New York piece here.

About MYnd Analytics, Inc.

MYnd Analytics, Inc. ( provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications. 

To read more about the benefits of this patented technology for patients, physicians and payers, please visit

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Media Contact:
Lauren Jenkins
(202) 596-5669

Primary Logo